1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Patient Assistance Programs (Medication, Premiums, Co-pays, Diagnostic Testing, Travel) is sponsored by National Organization for Rare Disorders (NORD). NORD's Patient Assistance Programs provide financial assistance to help patients obtain life-saving or life-sustaining medication they could not otherwise afford, and also assist with insurance premiums and co-pays, diagnostic testing, and travel for clinical trials or consultat…
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Gravity Forms and ReCAPTCHA WordPress sets this to indicate that you are logged in and who you are, for most interface use. ytidb::LAST_RESULT_ENTRY_KEY Description is currently not available. No description available.
No description available. Description is currently not available. No description available.
No description available. No description available. Description is currently not available.
Description is currently not available. Description is currently not available. Description is currently not available.
Description is currently not available. 7afc35f4-eae6-4f81-b934-2be0ba970f3d Description is currently not available. No description available.
No description available. No description available. No description available.
wp-postpass_7a45526c2bbf3827a311ad10171fe873 Description is currently not available. Description is currently not available. No description available.
No description available. No description available. Description is currently not available.
Description is currently not available. Description is currently not available. Description is currently not available.
Description is currently not available. Description is currently not available. Description is currently not available.
No description available. gfm-pro-checkout-prefetch-data-83644 Description is currently not available. gfm-pro-dw-available-83644 Description is currently not available.
Description is currently not available. Description is currently not available. Description is currently not available.
Description is currently not available.
According to the current listing, eligibility includes: Individuals living with rare diseases who need assistance with medication, insurance, diagnostic testing, or travel for clinical care or specialist visits. Confirm the full requirements in the official notice before applying.
Patient Assistance Programs (Medication, Premiums, Co-pays, Diagnostic Testing, Travel) is funded by National Organization for Rare Disorders (NORD). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Mentored Clinical Research Award (MCRA) supports patient-oriented vision injury research conducted by highly motivated military or civilian clinicians in training. The MCRA may be used to support a standalone study of high impact to vision injury care or the generation of clinical research data in preparation for a more expansive study. Research must align with at least one of the FY26 VRP Focus Areas. The MCRA may not be used to support preclinical research or clinical trials. Distinctive Features: · Key personnel must include an established clinician or Ph.D. clinical scientist, who will serve as Principal Investigator (PI) and a clinician in training (e.g., a fellow, resident, junior clinician, clinician in a Ph.D. program), who will conduct the proposed research under mentorship of the PI, with support from supporting personnel as appropriate. · The clinician in training should have sufficient time remaining in their training program to complete the research proposed under the MCRA. · Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact and Personnel. · Programmatic review criteria include adherence to the intent of the MCRA, contribution to program portfolio, relative impact and relevance to military health. · Applicants must submit documentation of Institutional Review Board (IRB)/Ethics Committee (EC) approval or exemption by January 1, 2027, in order for the MCRA application to be considered for funding. https://cdmrp.health.mil/pubs/press/2026/vrppreann Funding Opportunity Number: HT942526VRPMCRA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $150K total program funding.
Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Platform Clinical Translation Award supports the translational development and/or early-phase clinical trials for broadly applicable clinical technologies that will address urgent and complex needs related to two congressionally directed FY26 PRMRP topic areas. The platform product in development should address one of the FY26 PRMRP portfolio-specific strategic goals and address the health care needs of military Service Members, Veterans and their Families.Distinctive Features:Allows for multiple Principal Investigators (PIs). The proposed experiments may represent a single project led by a single PI, or it may consist of partnerships between principal investigators that will occur synergistically to advance a platform product. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. Up to two additional PIs can be identified as Partnering PIs. If recommended for funding, each PI will be named on separate awards to the recipient organization(s).Requires a PI-convened external advisory board with patient advocate participation. The patient advocate must be a person living with, or a family member or caretaker of someone with, a disease or condition addressed in one of the applicant-selected congressionally directed FY26 PRMRP topic areas.Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $30M to fund approximately two Platform Clinical Translation Award applications with total cost caps of $15M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with a maximum of $8M in FY26, with the remaining budget to be funded out of future fiscal years depending upon meeting performance-based milestones and availability of future funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027. Funding Opportunity Number: HT942526PRMRPPCTA. Assistance Listing: 12.420. Funding Instrument: CA,G. Category: ST. Award Amount: $30M total program funding.
Anthropic is giving rare-disease researchers and early-stage biotechs up to $50,000 in Claude API credits over six months — not cash, but compute. Here is how the two-track program works, who is eligible, what the credits can and cannot do, and how it fits a fast-growing new category: the compute-as-grant model reshaping how AI-for-science actually gets funded.
Read articleThe Department of Energy's Office of Critical Minerals and Energy Innovation is spending to break America's 95% dependence on foreign rare earths. The strategy is unusual: recover critical materials from the waste streams of coal plants, smelters, and refineries that already exist. Here is the full funding architecture — the $75M just awarded, the $500M battery-materials round, the $1B pipeline behind them — and how an industrial operator should position for what comes next.
Read articleOn June 2, 2026, the Department of Energy's Office of Critical Minerals and Energy Innovation selected two demonstration-scale facilities — Phoenix Tailings (with MIT and the University of Minnesota) for $66 million, and the Colorado School of Mines (with ElementUSA, PNNL, Principal Mineral, and Rare Earth Technologies Inc.) for the balance — under the Rare Earth Elements Demonstration Facility Program. Both projects pull rare earths from industrial waste — red mud at the Gramercy refinery in Louisiana, and a mix of mine and refining tailings elsewhere. Here is what the selections tell researchers, small businesses, and downstream magnet customers about where DOE thinks the chokepoint actually is, and what to do before the next demonstration-scale solicitation opens.
Read article